{
  "id": 2318162,
  "title": "Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target",
  "url": "https://urgent.news/2026/08/21/jefferies-initiates-coverage-on-anthem-biosciences-with-a-rs-1-050",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-21T05:19:56.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/stocks/news/jefferies-initiates-coverage-on-anthem-biosciences-with-a-rs-1050-target/articleshow/133393891.cms"
  },
  "original_language": "en",
  "account": "Jefferies has begun providing coverage for Anthem Biosciences with a Buy rating and a target price of Rs 1,050. This implies a potential upside of around 20% from the company's current market price of Rs 874.15. The brokerage cites Anthem's differentiated capabilities across small- and large-molecule therapeutics, strong return ratios, and a promising growth runway as the reasons for their bullish stance.",
  "summary": "Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the company’s integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}